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A B S T R A C T   
Background: Numerous pathologies result in multiple-organ failure, which is thought to be a direct consequence 
of compromised cellular bioenergetic status. Neither the nature of this phenotype nor its relevance to survival are 
well understood, limiting the efficacy of modern life-support. 
Methods: To explore the hypothesis that survival from critical illness relates to changes in cellular bioenergetics, 
we combined assessment of mitochondrial respiration with metabolomic, lipidomic and redox profiling in 
skeletal muscle and blood, at multiple timepoints, in 21 critically ill patients and 12 reference patients. 
Results: We demonstrate an end-organ cellular phenotype in critical illness, characterized by preserved total 
energetic capacity, greater coupling efficiency and selectively lower capacity for complex I and fatty acid 
oxidation (FAO)-supported respiration in skeletal muscle, compared to health. In survivors, complex I capacity at 
48 h was 27% lower than in non-survivors (p = 0.01), but tended to increase by day 7, with no such recovery 
observed in non-survivors. By day 7, survivors’ FAO enzyme activity was double that of non-survivors (p =
0.048), in whom plasma triacylglycerol accumulated. Increases in both cellular oxidative stress and reductive 
drive were evident in early critical illness compared to health. Initially, non-survivors demonstrated greater 
plasma total antioxidant capacity but ultimately higher lipid peroxidation compared to survivors. These alter-
ations were mirrored by greater levels of circulating total free thiol and nitrosated species, consistent with 
greater reductive stress and vascular inflammation, in non-survivors compared to survivors. In contrast, no clear 
differences in systemic inflammatory markers were observed between the two groups. 
Conclusion: Critical illness is associated with rapid, specific and coordinated alterations in the cellular respiratory 
machinery, intermediary metabolism and redox response, with different trajectories in survivors and non- 
survivors. Unravelling the cellular and molecular foundation of human resilience may enable the development 
of more effective life-support strategies.   
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1. Introduction 
Critical illness is poorly defined but generally refers to a condition in 
which acute organ dysfunction, involving two or more organs, has 
occurred to the degree that supportive intervention is required on an 
intensive care unit (ICU) [1]. Many different pathologies may lead to 
this heterogeneous state. No definite explanation for multiple-organ 
failure has been found, but it generally involves tissue injury (from 
trauma, infection, or other inflammatory cause), triggering a systemic 
humoral and inflammatory response, with subsequent alterations to 
macro- and microcirculatory blood flow and tissue oxygen demand [2]. 
It is associated with high short-term mortality (approximately 35–65%) 
even with provision of artificial organ support [3,4]. 
More than five million patients are admitted to an ICU each year in 
the USA and the cost of hospital admissions to ICUs accounts for almost 
half of all hospital expenditure [5]. The recent COVID-19 pandemic has 
demonstrated the devastating impact of critical illness on a global scale. 
It also highlights the pressing need to develop more sophisticated stra-
tegies to support organ function in this, still poorly understood, 
life-threatening state. The impact of critical illness extends far beyond 
the ICU, with many survivors suffering long-term physical and psycho-
logical impairment for years following discharge [6], creating a major 
economic burden, on top of untold suffering of the individuals and their 
families. Despite clear statements that what we require is a better un-
derstanding of the basic cellular mechanisms that underlie critical 
illness [7], very little progress has been made in the last decade [8]. 
Cellular bioenergetic failure is purported to underlie organ 
dysfunction in critical illness [9,10], therefore the majority of support-
ive therapy has traditionally focused on the augmentation of oxygen 
transport and macrocirculatory blood flow, with the avowed aim of 
promoting cellular ATP production by mitochondrial oxidative phos-
phorylation. However, clinical trials have failed to demonstrate that this 
approach leads to a tangible improvement in patient survival [11]. An 
alternative hypothesis is that recovery from multiple-organ failure de-
pends upon the ability of cells to adapt to the pathophysiological stress 
generated by critical illness, which imposes extreme deviations in 
multiple factors influencing cellular bioenergetic demand and supply. 
Cellular adaptation to analogous forms of bioenergetic stress, such as 
that imposed by environmental hypoxia, has been demonstrated in 
studies of acclimatizing humans [12] and in human cells ex vivo [13]. 
Cellular accommodation to the specific bioenergetic demands of critical 
illness would require a physiological switch to enable adequate adap-
tation at multiple levels of biological organization. Reduction-oxidation 
(redox) reactions are thought to be central to the signaling and syn-
chronization of processes within cells and between different body 
compartments to meet altered bioenergetic and metabolic demands in 
response to stress [14]. A complex series of cascading redox interactions 
between different bioactive species, across multiple compartments 
within the body, represents a plausible candidate mechanism for the 
integration of critical illness inflammatory and stress signaling to coor-
dinate putative adaptations in cellular bioenergetics. 
Without reliable markers of cellular performance in the ICU setting, 
investigations of the bioenergetic response to critical illness have been 
limited and the results inconsistent. Generally, skeletal muscle physi-
ology has been used as a surrogate for other, arguably more essential, 
organs, due to the relatively low risk of harm from obtaining tissue 
samples in critically unwell patients. Lower intramuscular ATP con-
centrations have been measured in patients with sepsis-induced multiple 
organ failure compared to patients undergoing elective surgery [15], 
and in a heterogenous group of critically ill patients compared to 
ambulant patients with respiratory disease [16]. However, supranormal 
intramuscular ATP concentrations have also been described during 
critical illness, at least in patients who went on to survive [17]. As a 
surrogate marker of bioenergetic capacity, tissue ATP concentrations are 
limited by the fact that they reflect the steady-state value of both pro-
duction and consumption, which are highly regulated and buffered by 
phosphocreatine [18]. Systemic redox alterations, as evidenced by 
increased concentrations of oxidized macromolecules, have been 
implicated in the genesis and perpetuation of sepsis, a common cause of 
critical illness, and oxidative stress has also been linked to changes in 
mitochondrial function [19]. To determine whether bioenergetic ca-
pacity truly represents a viable target to promote survival, a more 
comprehensive understanding is required of how these complex cellular 
processes operate in humans, in the real-world context of 
life-threatening stress. 
We hypothesized that patients with critical illness (defined by 
multiple-organ failure) would exhibit a distinct cellular phenotype, 
encompassing bioenergetic, metabolic and redox function, which differs 
from health, and that specific changes in this phenotype would distin-
guish eventual survivors from non-survivors. To this end, we combined 
direct assessment of mitochondrial respiration with contemporaneous 
characterization of relevant metabolic pathways (including glycolysis, 
the tricarboxylic acid (TCA) cycle, fatty acid oxidation (FAO), and amino 
acid metabolism) and redox status in skeletal muscle from patients with 
acute onset multiple-organ failure and from a healthy reference group. 
We also investigated the relationship between cellular processes and the 
systemic compartment by concomitant assessment of plasma lipidomic 
and redox profiles with oxidative stress markers in erythrocytes. 
2. Results 
2.1. Integrated bioenergetic, metabolic and redox phenotyping in patients 
with critical illness 
We recruited adult ICU patients with acute onset, severe physiolog-
ical derangement (Table 1), from any primary cause (Table 2), requiring 
at least two forms of artificial organ support (n = 21). The study protocol 
is outlined in Fig. 1. A vastus lateralis muscle biopsy was performed 
within 48 h following admission to the ICU and repeated, when possible, 
at day 5–7 (n = 12). Blood was sampled from arterial and central venous 
catheters at the same timepoints, with an additional sample taken at day 
3–4. Detailed clinical data were also collected at baseline, day 3–4 and 
day 5–7 and are shown in Supplementary Table 1. Muscle biopsies and 
demographic and basic clinical data were taken from a healthy reference 
group of age and sex-matched patients undergoing elective hip surgery 
Table 1 
Baseline characteristics of critically ill and healthy reference cohorts.  
Participant characteristics Critically ill (<48 h ICU 
admission) (n = 21) 
Reference group 
(n = 12) 
Age, y mean (95% CI) 61.4 (54.4–68.4) 59.5 (49.8–69.2) 
Female sex, n (%) 8 [38] 7 [58] 
Height, m median (IQR) 1.75 (1.66–1.77) 1.73 (1.67–1.77) 
Weight, kg median (IQR) 70.6 (63.8–90) 78.0 (65.7–96.8) 
BMI, kg/m2 median (IQR) 24.2 (22.0–29.5) 25.4 (22.3–31.9) 
Organ insufficiency prior to 
admission, n (%) 
3 [14] 0 (0) 
Independent prior to hospital 
admission, n (%) 
20 (95) 12 (100) 
Co-morbidities n (%) 
Hypertension 11 [54] 1 [8] 
Ischemic heart disease/ 
arrythmia 
6 [29] 1 [8] 
Respiratory 6 [29] 2 [17] 
Diabetes 4 [19] 0 (0) 
Chronic renal impairment 3 [14] 0 (0) 
Mechanically ventilated n (%) 21 (100) 12 (100) 
Intravenous antibiotic therapy 
n (%) 
19 (90) 12 (100) 
Propofol administered n (%) 11 [52] 12 (100) 
Muscle relaxant within 
previous 24 h n (%) 
9 [43] 12 [12] 
Nutrition within previous 6 h 
n (%) 
13 [62] 0 (0) 
BMI: Body mass index. 
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under general anesthesia (n = 12, Table 1). In the cohort of patients with 
critical illness, the severity of organ failure at enrolment was high, ac-
cording to APACHE II (mean 28; s.d. 7) and SOFA scores (mean 13; s.d. 
3), and 12 patients died prior to hospital discharge. Non-survivors were, 
on average, 15 years older than survivors, with a greater severity of 
illness according to APACHE II score (Supplementary Table 2). No pa-
tient was hypoxemic, as judged by arterial partial pressure of oxygen, 
peripheral arterial oxygen saturation or calculated arterial oxygen 
content (Supplementary Table 2). 
2.2. The bioenergetic phenotype in the first 48 h of critical illness differs 
from health 
Oxygen flux (JO2) was measured in saponin-permeabilized muscle 
fibers using high-resolution respirometry and a substrate-uncoupler- 
inhibitor protocol to determine the capacity of mitochondrial respira-
tion under different respiratory states and substrate-led pathways 
(Supplementary Table 3 and Supplementary Fig. 1). Individual compo-
nents of the bioenergetic machinery were investigated, e.g. complex I, II 
and FAO-supported pathways of electron flow; and leak (LEAK), 
oxidative phosphorylation (OXPHOS) and uncoupled electron transfer 
system (ETS) respiratory states. Contrary to the prevailing doctrine of 
cellular bioenergetic collapse in critical illness, the maximum capacity 
for oxidative phosphorylation (OXPHOSMAX per mg wet weight), under 
conditions of saturating convergent electron flow at the Q junction, did 
Table 2 
Primary diagnoses recorded for critically ill patients with acute organ failure.  
Primary pathology n (%) 
Infection 14 [67] 
Hemorrhage 3 [14] 
Coronary ischemia/arrhythmia/cardiogenic shock 8 [38] 
Respiratory 10 [48] 
Acute liver impairment 2 [9] 
Acute renal impairment 3 [14] 
Gastrointestinal/intra-abdominal 8 [38]  
Fig. 1. Study schedule for tissue and blood sample collection from critically ill patients and the healthy reference cohort.  
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not differ between patients with acute organ failure and the reference 
group (Fig. 2a). There was also no difference between the groups in 
terms of maximum capacity of the electron transfer system when 
uncoupled from ADP phosphorylation (ETSMAX per mg, Fig. 2b). In line 
with these findings, skeletal muscle ratios of [ATP]/[ADP] and [PCr]/ 
[ATP] were also preserved in critical illness (Fig. 2c and d). However, 
specific alterations to the mitochondrial oxidative phosphorylation 
machinery were evident within 48 h of developing organ failure. 
Coupling efficiency was higher in the critically ill cohort at 48 h 
compared to the reference group (ratio 0.91 v 0.88, p = 0.045, Fig. 2e). 
This reflected a relative reduction in LEAK respiration in early critical 
illness, which was 30% lower in critically ill patients than the reference 
group (p = 0.02, Fig. 2f). The relative capacity for complex I-supported 
respiration (OXPHOSCI/ETSMAX) was also 21% lower in the critically ill 
cohort at 48 h compared to the reference group (p = 0.009), whilst FAO- 
supported respiration (OXPHOSFAO/ETSMAX) was 34% lower in the 
critically ill cohort than in the reference group (p < 0.001, Fig. 2f). 
2.3. Specific and dynamic bioenergetic modifications associated with 
resilience 
In the first 48 h of critical illness, relative complex I capacity was 
27% lower in eventual survivors compared to non-survivors (p = 0.01, 
Fig. 3a). There was a trend toward a 40% lower relative FAO capacity in 
eventual survivors compared to patients who died (p = 0.06, Fig. 3b). 
The percentage change in these specific respiratory capacities, from 48 h 
to day 5–7, also differed significantly between survivors and non- 
survivors (Fig. 3). All survivors underwent an increase in their capac-
ity for complex I-mediated respiration (median change +24%; IQR 
10–35) in contrast to the non-survivors, in whom the diminished com-
plex I capacity persisted (median change − 1.8%; IQR -9.5-10.3, p =
0.016, Fig. 3c, e). Capacity for FAO-supported respiration underwent an 
increase in survivors by day 5–7 (median change +12%; IQR 11–28), in 
contrast to non-survivors who underwent a median change of − 8.5%; 
IQR -32 to − 6, p = 0.008, Fig. 3d,f). 
2.4. Lipid overload is a corollary of bioenergetic remodeling in acute 
organ failure 
Concomitant muscle and plasma lipidomic analyses provided insight 
into the metabolic consequences of the altered mitochondrial substrate 
utilization in critical illness. Targeted metabolomic analysis was carried 
out on muscle homogenates and open-profile lipidomics on muscle and 
plasma using ultra-high performance liquid chromatography mass 
spectrometry and relevant muscle enzyme activities were assessed using 
Fig. 2. Skeletal muscle bioenergetics in critical illness. 
Vastus lateralis muscle from healthy reference patients (n = 9, blue circles), 
critically ill patients within the first 48 h of ICU admission (n = 21, purple 
squares) and at day 5–7 (n = 12, pink triangles). Median (IQR). a, Maximum 
oxidative phosphorylation capacity, stimulated by saturating convergent elec-
tron entry to the Q junction via complexes I and II and expressed per mg wet 
weight (OXPHOSMAX per mass). b, Maximum capacity of the uncoupled elec-
tron transfer system (ETSMAX per mass). c, Ratio of ATP to ADP within skeletal 
muscle, d, Ratio of phosphocreatine (PCr) to ATP within skeletal muscle. e, 
OXPHOS coupling efficiency (OCE). f, Relative capacities for respiration sup-
ported by proton leak (LEAKFAO), fatty acid oxidation (OXPHOSFAO), complex I 
(OXPHOSCI) and complex II (ETSCII), expressed relative to ETSMAX. Box and 
whisker: healthy reference group (blue); acute organ failure patients within first 
48 h of admission (purple), and at day 5–7 (pink). Mann-Whitney test, two- 
tailed, *p < 0.05, **p < 0.01, ***p < 0.001 vs healthy reference group. (For 
interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 3. Bioenergetic divergence in survivors and non-survivors of critical illness 
Vastus lateralis muscle from survivors (n = 9, filled green target symbol) and 
non-survivors (n = 12, filled orange triangles) at < 48 h of ICU admission). 
Biopsy repeated at Day 5–7 in survivors (n = 4, open green target symbols) and 
non-survivors (n = 8, open orange triangles). Median (IQR). a, Relative capacity 
for respiration supported by complex I, expressed relative to ETSMAX, at < 48 h, 
b, Relative capacity for respiration supported by FAO, expressed relative to 
ETSMAX, at < 48 h c, Relative complex I respiratory capacity measured at both 
<48 h and Day 5–7. d, Relative FAO respiratory capacity measured at both <48 
h and Day 5–7. e, Percentage change in relative complex I respiratory capacity 
from <48 h to Day 5–7. f, Percentage change in relative FAO respiratory ca-
pacity from <48 h to Day 5–7. Mann-Whitney test, two-tailed. *p < 0.05, **p <
0.01. (For interpretation of the references to color in this figure legend, the 
reader is referred to the Web version of this article.) 
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spectrophotometric assays. In skeletal muscle, the reduced mitochon-
drial capacity for respiration supported by FAO in the first 48 h of 
critical illness was consistent with diminished activity of the FAO 
enzyme, 3-hydroxyacyl-CoA dehydrogenase (HADH, Fig. 4a), which was 
29% lower in the critically ill cohort compared to the reference group (p 
= 0.03). It was also associated with relative accumulation of medium 
(carbon (C) 7–12) and long (C13-20) chain acyl-carnitines compared to 
the reference group (p = 0.02 and < 0.001 respectively, Fig. 4b and c). 
Skeletal muscle lipidomic analysis also revealed accumulation of total 
diacylglycerol (DAG, C30-46), levels of which were markedly greater in 
the critically ill cohort than the reference group (p = 0.007, Fig. 4d). 
This picture of skeletal muscle lipid backlog fits with the observed 
diminished mitochondrial capacity for FAO. In support of the earlier 
finding that failure to recover FAO metabolism at day 5–7 was a hall-
mark of poor outcome, by day 5–7 HADH activity was 50% lower in non- 
survivors compared to survivors (p = 0.048, Fig. 4e). The progressive 
imbalance between lipid supply and demand also existed at the systemic 
level, as plasma lipidomic analysis revealed a markedly greater intensity 
of venous plasma total triacylglycerol (TAG, C37-62) in non-survivors 
compared to survivors at day 5–7 (p = 0.003, Fig. 4f). 
2.5. Alterations to intermediary metabolism are consistent with a cellular 
response to hypoxia 
Critically ill patients demonstrated hallmarks of a coordinated 
metabolic skeletal muscle response to hypoxia, with evidence for upre-
gulation of glycolysis and shunting of pyruvate away from the TCA cycle 
(and oxidative phosphorylation) toward lactate production, as demon-
strated by elevated levels of total glycolytic intermediates (3-fold greater 
in the critically ill cohort compared to the reference group, p = 0.01, 
Fig. 5a), particularly pyruvate, which occurred in parallel with reduced 
levels of early (6-carbon) TCA cycle intermediates, and reduced citrate 
synthase activity (Fig. 5b and c). In critical illness, elevation in the latter 
(5- and 4-carbon) metabolites of the TCA cycle, despite the depletion in 
the early intermediates (Fig. 5c), suggests the existence of an alternative 
pathway for replenishing the cycle, via α-ketoglutarate and increased 
malate-aspartate shuttle activity. Glutamine, and its precursor, gluta-
mate, were indeed lower in early organ failure (Fig. 5d), consistent with 
a diversion of amino acids to replenish the TCA cycle. 
2.6. Redox status is associated with survival in organ failure 
A complementary array of assays was used to assess different com-
ponents of redox status in muscle, plasma and erythrocytes. We found 
higher intramuscular levels of the oxidized component of the redox 
couple methionine/methionine sulfoxide in critically ill patients 
compared to the reference group (Fig. 6a). However, critically ill pa-
tients had even higher levels of the reduced form compared to the 
reference group (Fig. 6b and c). Instead of a simple shift toward un-
compensated oxidative stress in critical illness, suggested by previous 
single biomarker approaches, these findings indicate an enhanced 
adaptive redox drive within skeletal muscle, with upregulation of 
cellular antioxidant capacity in the face of an increased oxidative 
burden. The same process was demonstrated at the systemic level. Non- 
survivors showed greater levels of whole-body oxidative stress than 
survivors, in the form of lipid oxidation products in venous plasma 
(Fig. 6d), but, also greater plasma reducing capacity at <48 h (Fig. 6e). 
Together, these data suggest that an active upregulation of reducing 
power, in both tissue (muscle) and systemic (plasma) compartments, 
occurs in response to life-threatening stress and oxidant injury, with 
non-survivors succumbing despite even greater enhancement of 
reducing capacity. In another compartment, venous erythrocytes, there 
was also a non-significant trend towards higher reducing capacity in 
non-survivors in the first 48 h of critical illness, according to the relative 
concentrations of reduced/oxidized glutathione (Supplementary Fig. 2). 
In addition, changes in the concentration of the powerful antioxidant 
glutathione persulfide (GSSH) were observed with divergent trajectories 
between survivors and non-survivors, although this did not meet criteria 
for statistical significance. 
2.7. Nitric oxide production/metabolism related to survival but not 
bioenergetic alterations 
Although there was no difference in steady-state concentration be-
tween critically ill survivors and non-survivors at any timepoint in terms 
of venous plasma nitrite, nitrate or cGMP, total nitroso species in non- 
survivors were 178% higher than those in survivors at <48 h (p =
0.016, Fig. 7). The same pattern was seen in arterial plasma, with no 
differences in nitrite, nitrate or cGMP, suggesting no changes in NO 
availability (cGMP) or total body NO production (nitrate). By contrast, 
arterial plasma levels of total nitroso species in non-survivors were 
260% higher than those in survivors at < 48 h (p < 0.001) and 133% 
higher than non-survivors at day 3–4 (p = 0.04, Fig. 7). These differ-
ences attest to marked differences in vascular inflammatory status and 
associated nitrosative stress between the two groups. At day 3–4, serum 
Fig. 4. Skeletal muscle and systemic lipid signals in critical illness. 
a-e, Vastus lateralis muscle from healthy reference patients (n = 9, blue circles), 
critically ill patients within the first 48 h of ICU admission (n = 21, purple 
squares) and at Day 5–7 (n = 12, pink triangles). Metabolite values expressed 
relative to the average of the healthy reference group. a, Mass-specific activity 
of 3-hydroxyacyl-CoA dehydrogenase (HADH) in skeletal muscle. b, Intramus-
cular ratio of medium chain (carbon chain length 7–12) to total carnitines. c, 
Intramuscular ratio of long chain (carbon chain length 13–20) to total carni-
tines. d, Intramuscular intensity of diacylglycerols (DAG). e, Mass-specific 
HADH activity at < 48 h in survivors (n = 9, green filled target symbol) and 
non-survivors (n = 12, orange filled triangles), and at Day 5–7 (survivors, white 
target symbols, n = 4, non-survivors, white triangles, n = 12). f, Total tri-
acylglycerol (TAG) in venous plasma, in survivors (green circles; n = 9 at < 48 
h, 7 at Day 3–4, 6 at Day 5–7) and non-survivors (orange triangles; n = 11 at <
48 h, 8 at Day 3–4, 8 at Day 5–7). Median (IQR). Mann-Whitney test, two-tailed. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web 
version of this article.) 
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total free thiols (normalized per g protein) were also 43% higher in 
venous plasma of non-survivors compared to survivors (p = 0.01), and 
42% higher in the arterial plasma of non-survivors compared to survi-
vors (p = 0.04, Fig. 7). There were no significant associations between 
any of these plasma markers of NO production and metabolism and the 
redox ratios measured in skeletal muscle. 
2.8. Relationship between critical illness phenotype and markers of 
inflammation 
There was no difference between survivors and non-survivors in 
terms of the traditional clinical markers of inflammation, such as serum 
C-reactive protein (CRP) or white cell count (WCC), at any of the three 
timepoints, as shown in Supplementary Data Fig. 3. 
There was also no relationship between levels of these clinical in-
flammatory markers and any of the plasma indicators of redox status and 
NO metabolism, measured in critically ill patients. Thus, the differences 
between survivors and non-survivors appear unlikely to represent dif-
ferences in the magnitude of systemic inflammation alone. 
3. Discussion 
This work supports the concept that critical illness alters the ma-
chinery governing cellular bioenergetic capacity and substrate meta-
bolism and highlights specific modifications that are associated with 
human resilience during life-threatening stress. Despite the moderate 
number of patients investigated and the overall heterogeneity of the 
critically ill cohort, there was a coherent and internally consistent pro-
file of modifications associated with multiple-organ failure. This 
involved cellular respiratory capacity, intermediary metabolism and 
redox architecture, which differed from health; and although none of the 
critically ill patients were hypoxemic, the profile of alterations observed 
bore many similarities to the cellular response to hypoxia. Specific as-
pects of the critical illness phenotype appeared to confer resilience, with 
greater initial divergence from normality in complex I and FAO- 
supported respiratory capacity associated with survival. These partic-
ular mitochondrial modifications may promote bioenergetic efficiency 
with respect to oxygen consumption, and thus contribute to preservation 
of muscle energetics despite the diminished capacity for complex I 
mediated respiration. Increased coupling efficiency reflects a reduction 
in mitochondrial proton leak relative to OXPHOS and means a greater 
Fig. 5. Metabolic pathway alterations in 
skeletal muscle during critical illness. 
Vastus lateralis muscle from healthy refer-
ence patients (n = 9, yellow circles), criti-
cally ill patients within the first 48 h of ICU 
admission (n = 21, blue squares) and at Day 
5–7 (n = 12, pink triangles). Metabolites 
measured using ultra-high performance 
liquid chromatography mass spectrometry, 
and values expressed relative to the average 
of the healthy reference group. Median 
(IQR). a, Total glycolytic intermediates. b, 
Citrate synthase enzyme activity, measured 
spectrophotometrically, expressed relative 
to protein concentration, c, Intermediates of 
the tricarboxylic acid pathway, d, Selected 
amino acids. Mann-Whitney test, two-tailed. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001 vs the reference group. Enzyme 
key. CS: citrate synthase; Acon1: aconitase 1; 
Acon2: aconitase 2; ICDH: isocitrate dehy-
drogenase; ⍺-KGD SCS: ⍺-ketoglutarate de-
hydrogenase; SDH: succinate 
dehydrogenase; Fum: fumarase; MDH: ma-
late dehydrogenase. (For interpretation of 
the references to color in this figure legend, 
the reader is referred to the Web version of 
this article.)   
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proportion of the substrate and oxygen consumption that drive mito-
chondrial electron transport are channelled towards ATP production 
[20]. The substrate switch away from FAO will also increase bio-
energetic efficiency, as respiration supported by FAO produces fewer 
ATP molecules per mole of oxygen consumed, compared with carbo-
hydrate oxidation [21]. This pattern of substrate reprogramming is 
characteristic of a metabolic response to cellular hypoxia; it has been 
described in the heart of the human fetus developing under relatively 
low oxygen tensions in utero [22] and can be induced in adult human 
cardiac muscle in response to cellular oxygen limitation [23]. Himala-
yan Sherpas have a lower skeletal muscle capacity for FAO-supported 
respiration and greater coupling efficiency, compared to lowlanders; 
and this has been proposed to underpin their augmented cellular ener-
getics and superior performance under conditions of hypobaric hypoxia 
at high altitude [12]. 
The pattern of bioenergetic and metabolic modifications in critical 
illness suggests a potential role for hypoxia inducible factor-1α (HIF-1α) 
in coordinating this response. Intracellular levels of HIF-1α are known to 
increase in response to reduced cellular oxygen availability, and to 
activate the transcription of genes involved in the adaptive response to 
hypoxia [24]. In cell models of hypoxia, HIF has been shown to mediate 
responses which promote survival under hypoxic conditions and which 
bear a striking similarity to the critical illness skeletal muscle phenotype 
described in this work, including: increased efficiency of oxidative 
phosphorylation [25]; reduced FAO [26]; increased transcription of 
glycolytic enzymes and lactate dehydrogenase (promoting conversion of 
pyruvate to lactate) as well as pyruvate dehydrogenase kinase 1 
(shunting pyruvate away from mitochondria) [27,28]. Although none of 
the critically ill patients were hypoxemic, their tissue oxygen partial 
pressure was not measured. In multiple-organ failure, cellular oxygen 
supply may be limited, even when cardiac output and convective oxygen 
transport are resuscitated, due to microcirculatory disturbance and 
inflammation [29]. Intramuscular succinate levels, also a potential 
marker of cellular hypoxia during tissue ischemia [30], were similar in 
critically ill patients and the reference group. However, elevated skeletal 
muscle concentrations of HIF-1α have been described in a cohort of 
critically ill patients, similar to that in the current study, even in the 
presence of normal arterial oxygen indices [16]. An alternative pathway 
for HIF-stabilisation in this context could be mitochondrially-generated 
ROS, which have been implicated in the induction of the HIF 
transcriptional response [31], whilst ROS stabilise the HIF α-subunit 
even under normoxic conditions [32]. This mechanism would be 
consistent with the elevated production of cellular and systemic oxi-
dants in critical illness, demonstrated in the current study. 
Demonstration of reduced complex I respiratory capacity in the 
critically ill cohort was consistent with the reduced expression and ac-
tivity of complex I in frozen muscle previously reported in critical illness 
[15,33], with lower activity previously associated with greater severity 
of shock [17]. Here we demonstrated for the first time that these protein 
changes have functional relevance and translate into altered respiratory 
capacity in intact mitochondria. Instead of reflecting mitochondrial 
dysfunction, however, early downregulation of complex I in critical 
illness appears to be protective, with eventual survivors demonstrating 
significantly lower complex I capacity than non-survivors within the 
first 48 h. The reduced capacity for complex I-supported respiration in 
critical illness also fits in with the concept of a hypoxia-induced adap-
tation response [13]. Downregulation of complex I in skeletal muscle of 
lowlanders acclimatizing to hypobaric hypoxia has been described as an 
adaptive response to protect the cell against enhanced ROS production 
[34]. In human placental tissue, the mechanism underlying hypoxic 
downregulation of complex I has been shown to involve the 
HIF-responsive microRNA-210, which represses iron-sulfur protein as-
sembly of complex I under very low oxygen conditions [13]. However, 
the effects of HIF on the electron transport chain previously described 
are not specific to complex I, but encompass the downregulation of other 
respiratory complexes. In this work, however, the diminished complex I 
capacity occurred in isolation, whilst maximum respiratory capacity was 
preserved, with no evidence for a compensatory increase in contribution 
from complex II. The association of free-moving complexes into super-
complexes may be relevant to this phenomenon, as both the relative 
abundance and specific composition of supercomplexes have previously 
been shown to alter in response to changes in cellular metabolic demand 
[35,36]. 
An alternative explanation for isolated downregulation of complex I 
demonstrated in this work, is via active/deactive transition of complex I, 
whereby the catalytically active form of complex I undergoes deacti-
vation to a dormant state, when the activity of the respiratory chain is 
limited, such as during hypoxia [37]. The mechanism behind this 
transition is not completely understood, but involves conformational 
changes in mitochondrially encoded subunits, exposing a critical 
Fig. 6. Redox modifications during critical 
illness 
a-c, Vastus lateralis muscle from healthy 
reference patients (n = 9, blue circles), crit-
ically ill patients within the first 48 h of ICU 
admission (n = 21, purple squares) and at 
Day 5–7 (n = 12, pink triangles). Metabolites 
expressed relative to the average of the 
healthy reference group. Median (IQR). 
Mann-Whitney test, two tailed. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs 
healthy reference group. a, Intramuscular 
levels of the oxidation product of methio-
nine, methionine sulfoxide (MetSO), b, 
Intramuscular reduced methionine (Met) 
and c, Ratio of reduced Met to its oxidation 
product, MetSO, in skeletal muscle. d-e, 
Venous plasma redox markers in survivors 
(green circles; n = 9 at < 48 h, 7 at Day 3–4, 
6 at Day 5–7) vs non-survivors (orange tri-
angles; n = 11 at < 48 h, 8 at Day 3–4, 8 at 
Day 5–7). Median (IQR). Mann-Whitney, 
two tailed. *p < 0.05. d, Plasma lipid per-
oxides and e, total antioxidant capacity. (For 
interpretation of the references to color in 
this figure legend, the reader is referred to 
the Web version of this article.)   
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Fig. 7. Nitric oxide availability in survivors and non- 
survivors of critical illness 
Circulating concentrations of markers of NO production and 
metabolism in venous plasma from critically ill survivors 
(green circles; n = 9 at < 48 h, 7 at Day 3–4, 6 at Day 5–7) vs 
non-survivors (orange triangles; n = 11 at < 48 h, 8 at Day 
3–4, 8 at Day 5–7), and in arterial plasma from critically ill 
survivors (green circles; n = 9 at < 48 h, 7 at Day 3–4, 4 at 
Day 5–7) vs non-survivors (orange triangles; n = 12 at < 48 h, 
9 at Day 3–4, 8 at Day 5–7). a, venous nitrite, b, arterial ni-
trite, c, venous nitrate, d, arterial nitrate, e, venous cGMP, f, 
arterial cGMP, g, venous total nitroso species, h, arterial total 
nitroso species, i, venous total free thiols, j, arterial total free 
thiols (both corrected for protein). Median (IQR). Mann- 
Whitney, two tailed. *p < 0.05, **p < 0.01. ***p < 0.001.   
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cysteine residue on subunit ND3, which renders the deactive form sus-
ceptible to nitrosation and thiol oxidation [37]. Complex I is a major site 
for the generation of ROS, particularly superoxide [38]. Complex I can 
produce ROS by both forward and reverse electron flow, with the latter 
responsible for the oxidative burst upon reoxygenation [36]. 
Hypoxia-induced complex I deactivation is thought to drive ROS pro-
duction at complex III [38], and via reversal of TCA cycle de-
hydrogenases [39], resulting in stabilisation of HIF-1α [40]. In contrast, 
when complex I is in the deactive form, superoxide production from 
reverse electron flow is suppressed, and this is thought to protect 
mitochondria from excessive ROS production upon reoxygenation [37]. 
Taken together, the data presented here may be consistent with acute 
hypoxia in cells of critically ill patients triggering a deactive transition in 
complex I, resulting in ROS release and stabilisation of HIF, thereby 
generating the metabolic phenotype of downregulated FAO and 
increased glycolysis. 
The temporal nature of the respiratory modifications was crucial, 
with the early deviations in complex I and FAO capacities tending to 
recover by day 5–7 in survivors, whilst the downregulation tended to 
persist, or progress, in non-survivors at the later timepoint. The diver-
gent trend between survivors and non-survivors in the dynamics of these 
alterations reveals the importance of the timing of engagement and 
release of this “brake” for patient survival. The fact that non-survivors 
tended not to decrease complex I and FAO-dependent respiration as 
much as survivors during the first 48 h of critical illness may indicate 
faster and more effective hypoxic acclimation by survivors; who can 
then return to normal more rapidly. Non-survivors, on the other hand, 
appear to not adapt to cellular hypoxia so effectively, such that several 
days later, hypoxic acclimation is still ongoing. Inferior hypoxic accli-
mation in the non-survivors could contribute to greater energy imbal-
ance and cellular dysfunction. This may be further compounded by the 
cost of the diminished or delayed metabolic/bioenergetic modifications 
being prolonged over a longer time period. For example, glycolysis was 
upregulated in critically ill muscle, and may have contributed to the 
preservation of intramuscular energetics under oxygen limited condi-
tions. Anabolic pathways, such as the conversion of lactate to glucose via 
the Cori cycle, may require the investment of ATP in the liver [41]. 
Increased glucogenesis may also increase the metabolism of glutamate, 
glutamine and other glucogenic amino acids to replenish TCA cycle in-
termediates via anaplerosis. Their depletion may be part of the mecha-
nism of rapid muscle wasting in critical illness [42], as they play an 
important role in inhibiting protein degradation and stimulating protein 
synthesis [43]. Rapidly dividing cells such as immune cells and the cells 
of the gastrointestinal tract also have a high demand for glutamine as a 
substrate [43]. 
Another cost of increased mitochondrial efficiency could be related 
to the downstream sequelae of reduced mitochondrial preference for 
fatty acids as a respiratory substrate, with the accompanying impair-
ment in the skeletal muscle FAO pathway, and consequent accumulation 
of intramuscular medium and long-chain acylcarnitines and diac-
ylglycerol. The concept that failure to recover cellular FAO metabolism 
is a hallmark of poor outcome was supported by the finding that muscle 
HADH activity was significantly lower in non-survivors by day 5–7, and 
may have contributed to progression of imbalance between lipid supply 
and demand at the systemic level, with markedly greater intensity of 
venous total TAG at the later timepoint. Ectopic (non-adipose) lipid 
deposition has been associated with metabolic dysfunction and cell 
toxicity [44]. In particular, the accumulation of muscle DAGs in the 
present study may have further implications for metabolic regulation 
through insulin signaling, as muscle DAG accumulation has been linked 
to induction of insulin resistance via protein kinase C [45,46]. Acute 
onset insulin resistance is well documented in critical illness and has 
been attributed to activation of the hypothalamic-pituitary-adrenal axis 
[47]. The present study suggests an additional mechanism, although 
protein kinase C and insulin resistance were not measured. Reduced 
skeletal muscle FAO in organ failure was accompanied by accumulation 
of muscle branched-chain amino acids (BCAAs: leucine, isoleucine and 
valine, Fig. 5d). Unlike other amino acids, BCAAs are primarily 
metabolized in muscle, hence this finding implies reduced muscle con-
sumption. The reduced activity of HADH may contribute to impaired 
BCAA oxidation, which has also been associated with the development 
of insulin resistance [48–50]. High plasma TAGs can lead to ectopic lipid 
deposition in skeletal muscle, including the accumulation of DAGs via 
the activity of lipoprotein lipase [51,52]. Elevation of circulating TAGs 
is known to contribute to metabolic syndrome [53], and represents a risk 
factor for type 2 diabetes and cardiovascular disease [54]. In critically ill 
patients, exposure to intravenous lipid infusions has been shown to have 
a detrimental effect of enhancing inflammatory responses [55]. Indeed, 
the higher circulating levels of nitroso species in plasma of non-survivors 
compared to survivors, vis-a-vis similar concentrations of nitrite, nitrate 
and cGMP (indicative of no changes in either NO production or avail-
ability) are indicative of a greater level of oxidative stress with enhanced 
production of superoxide (and consecutive formation of peroxynitrite) 
due to vascular inflammation in non-survivors; whether inflammation is 
restricted to the endothelium or extends to also include smooth muscle 
and/or the adventitial compartment remains unknown. Endothelial 
dysfunction is a hallmark of vascular inflammation, associated with 
enhanced platelet and leukocyte activation, and has recently been 
advocated to be targeted in order to reduce organ failure in critical 
illness [56]. Taken together, these data support the concept that the 
initial survival advantage gained by augmenting bioenergetic efficiency 
may ultimately come at the cost of disruption of metabolic homeostasis 
and downstream signaling, which if sustained, is incompatible with life. 
Organ failure and risk of death have previously been associated with 
increased by-products of oxidative stress [57] and correspondingly, we 
found higher intramuscular levels of the oxidized components of the 
redox couple, methionine/methionine sulfoxide. However, instead of a 
simple shift towards uncompensated oxidative stress in organ failure, as 
suggested by previous studies using single biomarker approaches, this 
work demonstrated the presence of a compensatory increase in reduc-
tive drive within skeletal muscle in critical illness, suggesting upregu-
lation of cellular antioxidant capacity in the face of an increased 
oxidative burden. The same process was demonstrated at the 
whole-body level, with non-survival associated with greater oxidative 
injury (in the form of increased lipid oxidation products) alongside 
increased total reducing power in plasma. Together, these data suggest 
that an active upregulation of reducing power in both tissue (muscle) 
and systemic (plasma) compartments occurs in response to 
life-threatening stress and oxidant injury, with non-survivors succumb-
ing despite even greater enhancement of reducing capacity. 
This finding of exaggerated reducing power in non-survivors was 
mirrored by corresponding changes in plasma total free thiol levels 
(which largely reflect the concentration of the single free cysteine thiol 
of serum albumin) and was consistent with that of a previous study [58]. 
In contrast, the redox status alterations in a third compartment, venous 
erythrocytes, were indicative of progressive oxidative stress in 
non-survivors (Supplementary Fig. 2), which may be a result of 
systems-wide coupling of redox processes for whole-body balance (thus, 
the price for enhanced reducing capacity in one compartment is 
increased oxidative stress elsewhere) [14]. Importantly, as with tem-
poral divergence between survivors and non-survivors in bioenergetic 
modifications, erythrocyte glutathione redox status and concentrations 
of the powerful antioxidant, glutathione persulfide (GSSH) evolved into 
opposite directions in survivors and non-survivors, with considerable 
inter-individual heterogeneity (Supplementary Fig. 2). The complexity 
of these redox changes only becomes apparent from a high-resolution 
analysis of multiple redox components across different compartments, 
demonstrating the limitation of assessing ‘redox status’ by using a small 
number of biomarkers in isolation. 
H.T. McKenna et al.                                                                                                                                                                                                                            
Redox Biology 41 (2021) 101907
10
3.1. Limitations 
The observed differences between the critically ill phenotype and 
reference subjects, and between the survivor phenotype and non- 
survivors, must be interpreted with caution. The description of these 
phenotypes is limited by the fact that this is a single study, in a small 
group of highly heterogenous patients with a high attrition rate, which 
increases the risk of type II error. Despite this, statistically significant 
differences between survivors and non-survivors were detected in 
several variables; even at the third timepoint, when subject numbers had 
decreased, implying that for these variables at least, power was 
adequate. There was a high potential for confounding factors to influ-
ence outcomes: and although no relationship was demonstrated be-
tween, for example, bioenergetic changes and nutritional intake or 
medications, it is impossible to rule out that a combination of differences 
between the reference cohort and the organ failure cohort, other than 
acute organ failure, may have contributed to differences between the 
groups. The risk of type I error was increased by the multiple statistical 
tests and correlations tested within this dataset. However, in this 
exploratory study, where the aim was to discover potentially important 
differences, in a highly unstable clinical cohort, the priority was to 
optimise sensitivity to detect potential signals in an exploratory fashion, 
which can then be further evaluated in dedicated future studies. By 
using a combination of approaches to describe a complex phenotype, 
this data set also demonstrated considerable internal consistency with 
lower mitochondrial capacity for FAO-supported respiration accompa-
nied by lower FAO enzyme activity and evidence for incomplete 
breakdown of longer-chain carnitines in muscle, as well as accumulation 
of TAG in plasma. 
One important limitation of mitochondrial analysis using per-
meabilised muscle fibers is the loss of potentially relevant interactions 
between respiratory complex activity and TCA cycle intermediates, due 
to the washout of metabolites and cations. For example, our metab-
olomic analysis demonstrated an accumulation of the TCA cycle inter-
mediate, oxaloacetate, in the skeletal muscle of critically ill patients. 
Oxaloacetate is known to be a high affinity inhibitor of complex II [59], 
however in the ex vivo assessment of respiration, critically ill patients 
did not differ from the reference group in terms of complex II capacity 
(Fig. 1f, Table 3). 
Although the comprehensive phenotype of bioenergetic, metabolic 
and redox modifications described here suggest a possible role for 
hypoxic adaptation and metabolic regulation in the cellular response to 
critical illness, such a mechanism cannot be demonstrated using these 
data. Further elucidating this potential mechanism will require assess-
ment of other markers of HIF activation and its downstream targets. 
Although these pathways have not yet been explored in critically ill 
patients, they are thought to play a role in cellular adaptation to stress in 
humans in related contexts, such as acclimatization to hypobaric hyp-
oxia, fetal adaptation to the intrauterine environment and substrate 
switching in chronic heart failure [60]. 
4. Conclusion 
The failure to consider the potential relevance of intracellular 
adaptive modifications to stress in the context of critical illness may be 
preventing important therapeutic advances. From these data, evidence 
emerges for the existence of a specific end-organ cellular phenotype, 
expressed in real-world human critical illness, that is associated with 
stress resilience. Survival may rely on both the cellular ability to launch 
an appropriate adaptive response at the onset of a critical insult as well 
as the ability to switch it off and/or initiate appropriate counter- 
regulation in a timely manner, to allow metabolic recovery and mini-
mize harmful consequences of bioenergetic and redox compensation. To 
this end, it will be important to capture the time-course of events at 
multiple levels. Future studies should seek to confirm the current find-
ings in larger numbers of patients, embracing the complexity of 
bioenergetic and redox pathways to search for solutions to human sur-
vival and long-term health post critical illness. 
5. Methods 
5.1. Study subjects 
The study schedule is summarized in Fig. 1. All subjects were 
recruited from a tertiary referral teaching hospital in London, United 
Kingdom (the Royal Free Hospital), between March 2016 and 2017. A 
cohort of patients with organ failure were recruited from a mixed 
medical and surgical ICU. Inclusion criteria were adults (aged >18 yr) 
with acute onset, severe physiological impairment from any primary 
cause, requiring at least two forms of organ support (e.g. mechanical 
ventilation, vasopressor or inotropic support, renal replacement ther-
apy) admitted to the ICU for <24 h. Patients with severe coagulopathy, 
primary neuromuscular pathology, disseminated cancer, therapeutic 
immunosuppression or diagnosed mitochondrial disorder were 
excluded. The primary diagnoses of the organ failure cohort are sum-
marized in Table 2. The cohort of healthy reference subjects was 
recruited from the orthopedic department, and comprised adults un-
dergoing elective hip replacement. Skeletal muscle was sampled from 
these patients intraoperatively under general anesthesia. In brief, the 
reference patients had undergone recent induction of anesthesia with 
intravenous opiates (usually fentanyl) and propofol, muscle relaxation 
using atracurium or rocuronium, and placement of an endotracheal tube 
for mechanical ventilation and maintenance of anesthesia with volatile 
agents such as isoflurane, sevoflurane or desflurane. An audit carried out 
at the Royal Free Hospital, along with 28 other hospitals in England, 
during the time of the study, demonstrated the administration of a 
consistent fractional concentration of oxygen of 0.5 throughout surgery, 
which corresponded to a measured mean partial pressure of oxygen 
(PaO2) of 25 kPa in patients with an arterial catheter [61]. All elective 
surgical patients had fasted for at least 6 h prior to induction of general 
anesthetic. The demographics and baseline clinical characteristics of the 
critically ill cohort (at <48 h from ICU admission) and healthy reference 
Table 3 
Mass-specific respiration rates in the critically ill and reference cohorts.  
JO2 per mass (pmol/ 
s/mg wet weight) 
median (IQR) 
Reference 
group (n = 9) 
Critically ill 
patients < 48 h 
(n = 21) 
Critically ill 











9.25 (7.20–13.4) * 
OXPHOSCI 26.2 
(19.6–31.3) 
20.5 (17.3–23.5) 26.8 (22.0–30.8)## 
OXPHOSMAX 44.6 
(38.4–59.4) 








24.5 (22.5–27.8) 25.5 (22.2–32.3) 
Respiratory capacities generated by sequential addition of substrates, un-
couplers and inhibitors according to previously described SUIT protocol. JO2: 
oxygen consumption rate at steady state; LEAKFAO: capacity for respiration 
supported by proton leak, in the presence of malate and octanoyl carnitine and 
absence of ADP; OXPHOSFAO: capacity for oxidative phosphorylation supported 
by FAO, following addition of saturating ADP; OXPHOSCI: capacity for oxidative 
phosphorylation supported by complex I; following addition of saturating py-
ruvate and glutamate; OXPHOSMAX: maximum capacity for oxidative phos-
phorylation supported by complex I and complex II, following addition of 
succinate; ETSMAX: maximum capacity of the electron transport system uncou-
pled from oxidative phosphorylation, following titration of uncoupler; ETSCII; 
capacity of uncoupled electron transport system supported by complex II alone, 
following inhibition of complex I by rotenone. *p < 0.05, **p < 0.01 vs reference 
group; #p < 0.05, ##p < 0.01 vs critically ill patients within 48 h. 
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group are summarized in Table 1. In the critically ill cohort, skeletal 
muscle and blood were sampled within 48 h of admission to the ICU (n 
= 21), and repeated, when possible at day 5–7 (n = 12 for muscle, due to 
the death of 4 and withdrawal of 5 subjects). An additional blood sample 
was taken at day 3–4 (n = 16). The clinical characteristics, including 
relevant medication and nutritional intake, of the organ failure cohort at 
all three timepoints are summarized in Supplementary Table 1. Of the 
organ failure cohort tested within 48 h of admission to ICU, 12 died prior 
to hospital discharge. For the patients tested day 5–7 (n = 12), 8 died 
prior to hospital discharge. The clinical characteristics (measured at 
<48 h) of the survivors and non-survivors are summarized in Supple-
mentary Table 2. 
5.2. Muscle sample collection and preparation 
Biopsies of the vastus lateralis muscle were taken from the mid-thigh 
using Tilley-Henckel forceps under local anesthesia (1% lidocaine) of 
the skin and superficial muscle fascia. A 5 mm incision was made and 
100 mg wet-weight tissue was collected. The sample was divided, with 
50 mg allocated for immediate respirometric analysis and the remainder 
snap frozen in liquid nitrogen and stored at − 80 ◦C until later analysis. 
The muscle sample for respirometry was immediately placed in ice-cold 
biopsy preservation medium (BIOPS): [CaK2EGTA (2.77 mM), K2EGTA 
(7.23 mM), MgCl2.6H2O (6.56 mM), taurine (20 mM), PCr (15 mM), 
imidazole (20 mM), DTT (0.5 mM), MES (50 mM) and Na2ATP (5.77 
mM) at pH 7.10], which was filtered and stored at − 40 ◦C until use to 
prevent bacterial growth. 
5.3. Blood sampling and preparation 
Blood was sampled from the critically ill cohort via indwelling 
catheters (arterial and central venous catheters), placed as part of their 
treatment on the ICU. Aliquots were collected with EDTA as anticoag-
ulant and immediately subjected to centrifugation to obtain plasma 
(800×g for 15 min) and a red blood cell pellet, both of which were stored 
at − 80 ◦C until later analysis. 
5.4. High-resolution respirometry 
Skeletal muscle fiber bundles were prepared from the respirometry- 
designated sample according to previously described methods [62]. 
After permeabilization of the sarcolemmal membrane using saponin (50 
μg/ml, in ice cold BIOPS, rocked for 20 min at 20 rpm), fiber bundles 
were rinsed in respiration medium (MiR05, outlined below) blotted on 
filter paper and weighed using a microbalance (Mettler-Toledo). 
Respiration of fiber bundles was then measured in mitochondrial 
respiration medium (MiR05) containing EGTA (0.5 mM), MgCl2.6H2O 
(3 mM), K-lactobionate (60 mM), taurine (20 mM), KH2PO4 (10 mM), 
HEPES (20 mM), sucrose (110 mM) and defatted BSA (1g.L-1) at pH 7.4, 
using the substrate-uncoupler-inhibitor titration protocol described 
below. All assays were performed, in duplicate, using an Oxygraph O2K 
(Oroboros Instruments, Innsbruck), with oxygen concentration kept 
between 250 to 400 pmol to prevent diffusion limitation of respiration. 
Respirometry was performed by the same operator throughout the 
study. 
5.5. Substrate uncoupler inhibitor titration (SUIT) protocol 
Oxygen flux (JO2) of the permeabilized muscle fibers was measured 
in the presence of a specific sequence of substrates, uncouplers and in-
hibitors, to quantify the maximum capacity of different components of 
mitochondrial respiration. The sequence of chemicals used to simulate 
the different respiratory capacities is summarized in Supplementary 
Table 3 and a representative trace of skeletal muscle fiber JO2 measured 
during the protocol is illustrated in Supplementary Fig. 1. Malate (2 mM, 
Sigma M1000) and octanoyl carnitine (0.2 mM, Tocris 0605) were 
initially added to the respiration medium to simulate the leak-limited 
respiration (LEAK). This leak-limited respiration was supported by 
fatty acid oxidation substrates and referred to as LEAKFAO. Subsequent 
addition of ADP (10 mM, Sigma A2754), also at saturating concentra-
tion, generated JO2 which supported ATP synthesis, but limited by fatty 
acid oxidation, OXPHOSFAO. Addition of pyruvate (20 mM, P2256) and 
glutamate (10 mM, Sigma G1626) saturated electron entry to complex I 
(OXPHOSCI), and addition of succinate (20 mM, Sigma S2378) saturated 
convergent electron flow via complex I and II to the Q-junction 
(OXPHOSMAX). Cytochrome c (10 μM) addition was used as a quality 
control to confirm outer mitochondrial membrane integrity; all assays 
with an increase in oxygen consumption of >15% following cytochrome 
c addition were excluded from further analysis. Carbonyl cyanide-p- 
trifluoromethoxyphenylhydrazone (FCCP) was used (stepwise titration 
of 0.5 μM, Sigma C2920) to uncouple oxidative phosphorylation and 
investigate ETS capacity (ETSMAX). Finally, rotenone was added (0.5 μM, 
Sigma C2920) to inhibit complex I [and thus FAO] and isolate succinate- 
linked ETS capacity (ETSCII). The OXPHOS coupling efficiency was 
calculated as follows to give an indication of mitochondrial coupling: 
OXPHOS coupling efficiency = 1 – LEAKFAO/OXPHOSMAX. The 
maximum respiratory capacities (OXPHOSMAX and ETSMAX were 
expressed per mg wet weight of muscle tissue. Individual capacities were 
expressed relative to ETSMAX, to indicate their proportional 
contribution. 
5.6. Enzyme activity assays 
Enzyme activity assays were performed as described previously [63]. 
Briefly, ~10 mg of vastus lateralis from each individual was homoge-
nized with an Eppendorf pestle in an Eppendorf tube containing 300 μL 
of homogenization buffer containing Hepes (20 mM), EDTA (1 mM), and 
Triton X-100 (0.1% vol/vol). The samples were then centrifuged 
(380×g, 30 s, 4 ◦C), and the supernatant was collected. This supernatant 
was centrifuged again (380×g, 30 s, 4 ◦C), and the resulting supernatant 
was collected to obtain a homogeneous suspension. All assays were 
performed using a spectrophotometer (Evolution 220; Thermo Scienti-
fic) at 37 ◦C in a reaction volume of 1 mL. Citrate synthase activity was 
quantified with homogenate diluted to 10 μg of protein per mL in an 
assay buffer containing Tris (20 mM), 5,5′-dithiobis-2-nitrobenzoic acid 
(0.1 mM), and acetyl-CoA (0.3 mM) at pH 8.0. The reaction was initiated 
by the addition of oxaloacetate (0.5 mM), and the absorbance change at 
412 nm was measured. The 3-hydroxyacyl-CoA dehydrogenase (HADH) 
activity was assayed with homogenate diluted to 20 μg of protein per mL 
in an assay buffer containing imidazole (50 mM), NADH (0.15 mM), and 
Triton X-100 (0.1% vol/vol) at pH 7.4. The reaction was initiated by the 
addition of 0.1 mM acetoacetyl-CoA (0.1 mM), and the absorbance 
change at 340 nm was measured. Enzyme activity values were corrected 
to the protein concentration of the homogenate measured using the 
Quick Start Bradford protein assay (Bio-Rad). 
5.7. Mass spectrometry for skeletal muscle metabolomics 
A chloroform/methanol extraction was performed on snap frozen 
skeletal muscle (~30 mg) as described previously [12], followed by 
ultra-high performance liquid chromatography mass spectrometry 
(UHPLC-MS) [64,65]. The aqueous phase was analyzed separately using 
normal and reverse phase analysis. The aqueous and organic fractions 
were then combined for carnitine analysis. The protein pellet was 
re-suspended in RIPA buffer (Thermo Scientific) containing protease 
inhibitor (Roche) and protein concentration determined using a bicin-
choninic acid (BCA) assay (BCA1-1KT, Sigma). Data were processed 
using the Vendor software and normalized to protein concentration and 
to the intensity of internal standards. 
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5.8. Aqueous metabolite analysis 
Reverse phase analysis was performed as described previously [65]. 
Before the analysis, samples were reconstituted in 0.1 mL of a 10 mM 
ammonium acetate water solution containing a mixture of 8 internal 
standards at the concentration of 10 μM (Proline, Valine D8, Leu-
cineD10, Lys U13, Glutamic acid C13, Phen D5, Succinic acid D3, 
Serotonine D4). Normal phase analysis was performed using a Thermo 
scientific Vanquish™ UHPLC + series coupled with a TSQ Quantiva 
Triple Quadrupole Mass Spectrometer (Thermo Fisher Scientific, MA, 
United States) was used with an electrospray ionization (ESI) source, 
operated in positive and negative ion mode with polarity switching. The 
electrospray voltage was set to 3500 V for the positive ionization and to 
2500 V for the negative ionization. Nitrogen at 48 mTorr and 420 ◦C was 
used as a drying gas for solvent evaporation. The aqueous phase was 
analyzed with a BEH Amide (150 × 2.1 mm 1.7 μm) column. The column 
was conditioned at 30 ◦C. The mobile phase consisted of: (A) a 0.1 M 
aqueous solution of ammonium carbonate and (B) acetonitrile. The 
mobile phase was pumped at a flow rate of 600 μL/min programmed as 
follows: initially stayed at 20% of A for 1.5 min, then was subjected to a 
linear increase from 20% to 60% of A in 2.5 min and kept at this per-
centage for 1 min and then brought back to initial condition after 0.1 
min, followed by 3 min of equilibration.Xcalibur software (Thermo 
Fisher, version 4.1) was used for data acquisition. Putative recognition 
of all detected metabolites was performed using a targeted MS/MS 
analysis. Before the analysis, samples were reconstituted in 0.1 mL of an 
acetonitrile:1 M aqueous ammonium carbonate solution (7:3 v/v) con-
taining a mixture of 3 internal standards at the concentration of 10 μM 
(Glutamic acid C13, Succinic acid D3 and AMP). 
5.9. Carnitine analysis 
Samples were prepared as described previously [12]. A UHPLC +
series chromatography sstem coupled with a TSQ Quantiva Triple 
Quadrupole mass spectrometer (Thermo Fisher) was used with an ESI 
source, operating in positive and negative ionization mode at the same 
time. The electrospray voltage was set to 3500 V for the positive ioni-
zation and to 2500 V for the negative ionization. Nitrogen at 48 mTorr 
and 420 ◦C was used as a drying gas for solvent evaporation. The organic 
phases were analyzed with an ACE Excel 2C18 PFP (100A. 150 × 2.1 
mm 5μ) column kept at 30 ◦C. The mobile phase consisted of: (A) a 0.1% 
of formic acid in water solution and (B) a methanol solution. The mobile 
phase was pumped at a flow rate of 0.450 μL/min programmed as fol-
lows: initially stayed at 0.5% of B for 1 min, then was subjected to a 
linear increase from to 100% of A in 9 min and kept at this percentage 
for 2 min and then brought back to initial condition after 0.1 min. 
Thermo Scientific Xcalibur software was used for data acquisition. Pu-
tative recognition of all detected metabolites was performed using a 
targeted MS/MS analysis. Before the analysis, samples were recon-
stituted in 0.1 mL of a methanol: water solution (4:1 v/v) containing a 
labelled carnitine standard set B mix solution (CN, C2, C3, C4, C5, C8, 
C14, C16). 
5.10. Mass spectrometry for skeletal muscle and plasma lipidomics 
5.10.1. Sample preparation 
A chloroform/methanol extraction was performed, as stated above 
for muscle, on 20 μl snap frozen plasma. For both skeletal muscle and 
plasma, the dried organic fraction was reconstituted in 50 μL of meth-
anol/chloroform (1:1) and vortexed thoroughly. 10 μL of the sample was 
then diluted into 190 μL of isopropyl alcohol/acetonitrile/water (2:1:1) 
and briefly vortexed. 
5.10.2. Lipidomics analysis 
An LTQ Orbitrap Elite Mass Spectrometer (Thermo Fisher Scientific) 
was used in positive and negative modes. Metabolites were ionized by 
heated electrospray before entering the spectrometer. The source tem-
perature was set to 420 ◦C, and the capillary temperature to 380 ◦C. In 
positive mode, the spray voltage was set to 3.5 kV, while in negative it 
was 2.5 kV. Data were collected using the Fourier transform mass 
spectrometer (FTMS) analyzer. The resolution was set to 60,000 and the 
data was obtained in profile mode. The full scan was performed across 
an m/z range of 110–2000. For both modes, 5 μL of sample was injected 
onto a C18 CSH column, 2.1 × 50 mm (1.7 μM pore size) (Waters), 
which was held at 55 ◦C using an Ultimate 3000 UHPLC system (Thermo 
Fisher Scientific). The mobile phase comprise solvents A (acetonitrile/ 
water 60:40) and B (acetonitrile/isopropanol 10:90), run through the 
column in a gradient (40% B, increased to 43% B after 0.8 min, 50% B at 
0.9 min, 54% B at 4.8 min, 70% B at 4.9 min, 81% B at 5.8 min, raised to 
99% B at 8 min for 0.5 min before returning to 40% for 1.5 min). Total 
run time was 10 min, with a flow rate of 0.500 μL/min. In positive mode, 
10 mM ammonium formate was added to solvents A and B. In negative 
mode, 10 mM ammonium acetate was the solvent additive. Solvent 
additives were chosen based on current literature [66]. Before analysis, 
250 μl internal standard (IS) mix was added to each sample. This was 
composed of deuterated standards sourced from Avanti Polar Lipids 
(C16-d31 Ceramide, 16:0-d31–18:1 PA,16:0-d31–18:1 PC, 
16:0-d31–18:1 PE, 16:0-d31–18:1 PG, 16:0-d31–18:1 PI,14:0 PS-d54, 
and 16:0-d31 SM) and CDN Isotopes/QMX Laboratories (18:0-d6 CE, 
15:0-d29 FA, 17:0-d33 FA, 20:0-d39 FA, 14:0-d29 LPC-d13, 45:0-d87 
TG, 48:0-d83 TG, and 54:0-d105 TG). IS mix was made in 1:1 meth-
anol chloroform, and each standard was at 2.5 μg/ml. For processing, 
spectra were converted to.mzML files using MSConvert (Proteowizard) 
for subsequent analysis. XCMS software within R was used to process 
data and identify peaks. Peaks were identified based on an approximate 
FWHM of 5 s and a signal to noise threshold of 5. To improve peak 
identification, peaks had to be present in a minimum of 25% of the 
samples. Peaks were annotated by accurate mass and retention time 
using an in-house R script. Peak intensity was normalized to internal 
standards and, in the instance of skeletal muscle tissue, to protein 
concentration. 
5.10.3. Plasma nitric oxide status and redox markers 
Production, metabolism and bioavailability of nitric oxide (NO) were 
assessed in arterial and venous EDTA plasma by measurement of its 
oxidative breakdown products, nitrite and nitrate (using high pressure 
liquid chromatography), total nitrosated species (by gas phase chem-
iluminescence following reduction by triiodide) and cyclic GMP (by 
ELISA), as described in detail elsewhere [67,68]. Samples for NO 
metabolite analysis were pre-treated with N-ethylmaleimide (NEM), 
whilst those for other biomarkers were used immediately after thawing 
without further derivatization. For the former, frozen plasma aliquots 
were thawed in the presence of excess NEM in PBS to achieve a final 
concentration of 10 mM NEM. This was accomplished by adding a 100 
mM NEM stock solution in 10 mM PBS (pH 7.40) at a 1:10 (v:v) ratio to a 
sample aliquot after thawing, followed by vortexing and 15 min incu-
bation. Concentrations of total nitrosation products (RXNO) were 
measured by gas-phase chemiluminescence NO following reductive 
denitrosation using a septum sealed reaction chamber containing triio-
dide in glacial acetic acid constantly purged with N2. Samples were 
further incubated with acidic sulfanilamide to remove excess nitrite 
from NEM-treated EDTA plasma by reaction with acidic sulfanilamide 
prior to analysis, followed by injection of treated aliquots into the re-
action chamber. The amount of NO liberated from low-molecular weight 
and protein nitroso-species were quantified by a gas-phase chem-
iluminescence analyser (CLD 77 am sp, EcoPhysics), as previously 
described [67,68]. Nitrate and nitrite concentrations were quantified 
using a dedicated high-performance liquid chromatography analyser 
(ENO20, Eicom) – ion chromatography equipped with an in-line Cd/Cu 
column for nitrate reduction and Griess diatozation coupling reaction 
following sample deproteinization by precipitation with methanol and 
centrifugation at 16000×g for 20 min as noted previously [68]. All 
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glassware, collection tubes and pipettes rinsed with ultrapure water to 
reduce background contaminant levels of nitrite and nitrate. Concen-
trations of total free thiols were determined spectrophotometrically, 
using dithionitrobenzoic acid (DTNB) as described previously [69]. 
Plasma protein was quantified using the Coomassie (Bradford) Protein 
Assay Kit (ThermoScientific, Pierce Technology, Illinois, USA). Con-
centration of cGMP was quantified using a commercially available 
competitive ELISA immunoassay kit (R&D Systems, Abingdon, UK), and 
followed according to manufacturer’s instructions. Plasma total anti-
oxidant capacity was measured by the Ferric Reducing Activity of 
Plasma (FRAP) assay as previously described [70]. This assay is based on 
the principle that the reduction of ferric (Fe3+) to ferrous (Fe2+) ions at 
low pH results in the formation of an intense blue-colored ferrous--
tripyridyltriazine complex with a maximum absorption at 593 nm. 
Sample FRAP was quantified by comparing the absorbance of the 
reacted sample at 593 nm with a standard curve of known concentration 
of ferrous ions. Plasma lipid peroxidation was evaluated by measuring 
the thiobarbituric acid reactive substances (TBARS) as described pre-
viously [71]. A breakdown product of lipid peroxides, malondialdehyde 
(MDA) within a biological sample reacts with thiobarbituric acid (TBA), 
at high temperature and acidic conditions to form a 1:2 MDA-TBA 
adduct, with maximum absorption at 532 nm. TBARS were quantified 
in plasma, following this reaction, by comparing the absorbance at 532 
nm in the sample with a standard curve of solutions of known concen-
tration of MDA. Plasma biomarker concentrations were quantified in a 
staggered fashion to ensure reproducible processing times. Daily cali-
brations with authentic standards were performed for all biochemical 
assays. Analyses were performed in triplicate, and values averaged 
except for nitrite, nitrate and total nitroso species, where only a single 
determination was performed due to sample volume limitations. 
5.10.4. Thiol redox status and glutathione persulfide concentrations in 
erythrocytes 
Thiol redox status in erythrocytes was measured using ultra-high 
performance liquid chromatography tandem mass spectrometry 
(UPLC-MS/MS), as described in detail elsewhere [72]. Briefly, reduced 
and oxidized glutathione, cysteine and homocysteine as well as sulfide 
were quantified following hypotonic lysis of frozen erythrocyte pellets; 
lysis was accomplished by addition of ice-cold 1 mM ammonium phos-
phate buffer pH 7.40 containing 10 mM N-ethylmaleimide (NEM)/2 mM 
EDTA at a 1:4 (v:v) ratio. NEM alkylates free sulfhydryl groups, pre-
venting artificial autoxidation during the thawing process and 
enhancing ionization efficiency. Derivatized samples were spiked with 
internal standards, subjected to ultrafiltration for protein removal and 
injected onto UPLC-MS/MS. The same mass spectrometry platform was 
used for measurement of inorganic (S22− ) and organic (cysteine and 
glutathione-SSH) persulfides. Erythrocytes were lysed by addition to the 
frozen pellet of ice-cold MQ water supplemented with 10 mM iodoace-
tamide (IAM) and 1 mM tyrosine at a 1:4 (v:v) ratio. IAM is used to 
derivatize persulfide [73], while tyrosine stabilises polysulfide adducts 
[74]. Samples were subjected to ultrafiltration and injected onto 
UPLC-MS/MS. Sulfide and persulfide was analyzed using the chroma-
tography and multiple reaction monitoring conditions previously 
described [73]. Glutathione, cysteine, glutathione persulfide and 
cysteine persulfide were identified using the mass transitions of m/z 
365.0 → 235.5 for GS-IAM, m/z 397.0 → 267.5 for GS-S-IAM and m/z 
178.8 → 90 for CyS-IAM and m/z 210.8 → 90 for CysSS-IAM, respec-
tively; retention times were 1.35, 1.49, 1.75, 2.11, 2.45 and 2.52 for 
CyS-IAM, CySS-IAM, GS-IAM, S-(IAM)2, GSS-IAM and SS-(IAM)2, 
respectively. No cysteine persulfide was detected in erythrocytes. 
Whereas erythrocytic glutathione concentrations measured by the IAM 
method and the NEM method were almost identical, persulfide con-
centrations are estimates only due to the lack of stable-isotope labelled 
standards. 
5.10.5. Statistics 
Given the paucity of deep phenotyping studies in critically ill pa-
tients in the published literature, in particular, using the multifaceted 
approach planned in this investigation, it was not possible to perform a 
single statistical assessment to ensure adequate power to detect differ-
ences between the groups, using all of the assays. The approach chosen 
to determine a minimum sample size, was to base the calculation on the 
most important variables of interest. Given that this was a study of po-
tential bioenergetic adaptation, the capacity for respiration supported 
by proton leak (later defined as LEAKFAO) and fatty acid oxidation 
(OXPHOSFAO), and the specific activity of the HADH enzyme (repre-
senting the capacity of the FAO metabolic pathway) were chosen to 
represent the three most important aspects of a putative bioenergetic 
and metabolic phenotype in critical illness. “Normal” values for these 
variables, in a cohort of healthy volunteers at sea level, were previously 
determined by our own research group, using identical assays and 
protocols to those in this study [12]. The distributions of these variables 
were also determined in a population of Himalayan Sherpas, taken to 
represent an important phenotype of bioenergetic-metabolic adaptation 
to hypoxic stress. The differences in these variables demonstrated in 
Sherpas compared to lowlanders may have (i) whole-body functional 
significance, as Sherpas demonstrate enhanced hypoxic tolerance, and 
(ii) mechanistic plausibility, as they theoretically increase the efficiency 
of cellular energy production. Sample size calculations were performed 
using these values (taken from the data repository for this study and an 
online power calculation tool (https://clincalc.com/stats/samplesize. 
aspx) was used, based on two independent samples and a continuous 
endpoint. An alpha value of 0.05 was chosen (representing a 5% prob-
ability of a type I error; the false positive rate, or probability of detecting 
a difference between the critically ill and reference groups when it does 
not exist); and power of 80% was selected, as a standard threshold 
typically considered to represent an acceptable risk of type II error (or 
false negative rate) in clinical studies. Assuming an enrolment ratio of 
1:1, the minimum sample sizes for the three assays are summarized in 
Supplementary Table 4. A greater degree of variation was expected in 
the critically ill cohort than these cohorts (given the variation in ex-
pected stress, age, comorbidity and medications), and so these sample 
sizes were used to represent a minimum target for recruitment. 
Recruitment of critically ill patients was prioritised over reference pa-
tients, at an enrolment ratio of 2:1, in order to allow exploration of 
differences between survivors and non-survivors in the critically ill 
group. 
All data were tested for normality using the D’Agostino and Pearson 
omnibus normality test. Parametric continuous data were described 
using mean and 95% confidence intervals; non-parametric data using 
median and interquartile range. Frequency counts and percentages were 
used to describe categorical variables. The critically ill and healthy 
reference cohorts were compared using the Mann-Whitney test for in-
dependent data with non-parametric distributions. Survivors and non- 
survivors were compared using the Mann-Whitney test. Bivariate cor-
relations were assessed using Spearman’s test. All statistical tests were 
two-tailed and p values of <0.05 were considered statistically signifi-
cant. All statistics were performed using GraphPad Prism 8 software 
(GraphPad Software, Inc). 
5.10.6. Study approval 
All protocols received approval from the National Health Service 
(NHS) Health Research Authority (HRA). The study of patients with 
organ failure was reviewed by Camden and Islington NHS Research 
Ethics Committee (IRAS ID 159977, REC reference 14/LO/1832) and 
the study of healthy reference patients was reviewed by the East of 
England Cambridge South Research and Development Department 
(IRAS ID 208220; REC reference 16/EE/0317). Protocols also received 
local site approval from the Royal Free Hospital Research and Devel-
opment department. Participants with capacity gave written, informed 
consent. If participants lacked capacity, this was instead sought from 
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their allocated consultee (personal or professional). When capacity was 
regained, participants were again approached for written, informed 
consent for their data to be included in the study. 
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